{"id":4370,"date":"2026-11-17T09:00:00","date_gmt":"2026-11-17T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4370"},"modified":"2026-11-17T20:44:41","modified_gmt":"2026-11-18T00:44:41","slug":"regal-reports-an-overall-survival-gain-in-aml","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4370","title":{"rendered":"REGAL Reports an Overall Survival Gain in AML"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"512\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_SELLAS_GPS_Therapeutic_Indications-768x512.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4373\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_SELLAS_GPS_Therapeutic_Indications-768x512.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_SELLAS_GPS_Therapeutic_Indications-300x200.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_SELLAS_GPS_Therapeutic_Indications-1024x683.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_SELLAS_GPS_Therapeutic_Indications.png 1536w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>SELLAS Life Sciences<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Randomized Phase 3 topline (REGAL)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>WT1 peptide vaccine<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Galinpepimut-S (GPS)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>WT1<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Acute myeloid leukemia in second or later remission<\/p>\n<h4>Summary<\/h4>\n<p>SELLAS reported that the randomized Phase 3 REGAL trial met its prespecified overall-survival endpoint in 126 adults with AML in second or later remission who could not undergo allogeneic transplant. GPS versus investigator-choice treatment yielded HR 0.59, two-sided p=0.035, and median survival 24.0 versus 14.7 months. These are company topline data; full analyses remain pending.<\/p>\n<p>The open-label global study randomized 1:1 after salvage-induced CR2+ or CRp2+. Control options included observation, a hypomethylating agent, venetoclax and\/or low-dose cytarabine. Final analysis followed 80 deaths. The company said adverse events were predominantly grade 1\/2 injection reactions, with no new safety signal, and plans FDA discussion and a potential first-half-2027 BLA.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> a survival endpoint in a randomized Phase 3 population supports a real maintenance effect of WT1-directed T-cell priming, with a clinically relevant median separation.<\/p>\n<p><strong>Interpretation B:<\/strong> endpoint significance is fragile or confounded by post-randomization therapies, transplant, control heterogeneity, or imbalance. The reported p=0.035 leaves little statistical margin; detailed censoring, confidence interval, baseline strata, salvage regimens and subsequent therapy are not yet shown. Open-label treatment may affect ancillary care, although death is an objective endpoint. GPS is not demonstrated to supplant transplant or first-remission maintenance. WT1 expression, antigen heterogeneity, T-cell fitness after salvage and MRD status may influence response. Commercial scale depends on HLA breadth, dosing, access and label scope.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Galinpepimut-S is a four-peptide WT1 vaccine intended to induce CD4+ and CD8+ responses against residual WT1-expressing AML. Patients in second remission face high relapse risk; allogeneic transplant may be infeasible.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Verified company-reported primary endpoint; full dataset and independent peer review absent.<\/li>\n<li>Upgrade: survival curves, hazard-ratio CI, prespecified subgroup consistency and sensitivity analyses corroborate the effect.<\/li>\n<li>Downgrade: crossing hazards, material post-progression imbalance or treatment-related toxicity.<\/li>\n<li>Falsify broad platform inference if WT1 response fails to track clinical benefit.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>REGAL materially advances GPS in a narrow transplant-ineligible AML maintenance population. It does not establish approval or wider WT1-vaccine efficacy.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 5 of 5. Signal Direction: positive. Confidence in Facts: High. Confidence in Interpretation: Moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>SELLAS reported that the randomized Phase 3 REGAL trial met its prespecified overall-survival endpoint in 126 adults with AML in second or later remission who could not undergo allogeneic transplant. GPS versus investigator-choice treatment&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4373,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[76,1522,1361],"class_list":["post-4370","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-acute-myeloid-leukemia","tag-galinpepimut-s","tag-sellas-life-sciences"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4370"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4370\/revisions"}],"predecessor-version":[{"id":4386,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4370\/revisions\/4386"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4373"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4370"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4370"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}